LianBio (LIAN) Competitors $0.42 +0.01 (+1.92%) As of 07/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendInsider TradesSEC FilingsTrendsBuy This Stock LIAN vs. EDIT, FDMT, CTMX, OGI, VTYX, SLS, NVCT, PBYI, IPHA, and SPROShould you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Editas Medicine (EDIT), 4D Molecular Therapeutics (FDMT), CytomX Therapeutics (CTMX), Organigram Global (OGI), Ventyx Biosciences (VTYX), SELLAS Life Sciences Group (SLS), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), Innate Pharma (IPHA), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. LianBio vs. Its Competitors Editas Medicine 4D Molecular Therapeutics CytomX Therapeutics Organigram Global Ventyx Biosciences SELLAS Life Sciences Group Nuvectis Pharma Puma Biotechnology Innate Pharma Spero Therapeutics LianBio (NASDAQ:LIAN) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has better valuation and earnings, LIAN or EDIT? LianBio has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLianBioN/AN/A-$110.29M-$0.81-0.52Editas Medicine$32.31M6.70-$237.09M-$3.04-0.85 Which has more risk and volatility, LIAN or EDIT? LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Do analysts prefer LIAN or EDIT? Editas Medicine has a consensus price target of $4.70, indicating a potential upside of 81.82%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than LianBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Editas Medicine 2 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.31 Does the media favor LIAN or EDIT? In the previous week, Editas Medicine had 5 more articles in the media than LianBio. MarketBeat recorded 5 mentions for Editas Medicine and 0 mentions for LianBio. Editas Medicine's average media sentiment score of 0.67 beat LianBio's score of 0.00 indicating that Editas Medicine is being referred to more favorably in the news media. Company Overall Sentiment LianBio Neutral Editas Medicine Positive Is LIAN or EDIT more profitable? LianBio has a net margin of 0.00% compared to Editas Medicine's net margin of -701.06%. LianBio's return on equity of -33.17% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets LianBioN/A -33.17% -30.19% Editas Medicine -701.06%-139.24%-63.87% Do institutionals & insiders have more ownership in LIAN or EDIT? 74.8% of LianBio shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 2.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryLianBio and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks. Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIAN vs. The Competition Export to ExcelMetricLianBioBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.39M$127.88M$5.50B$9.01BDividend YieldN/A3.74%5.39%4.11%P/E Ratio-0.523.4127.4220.07Price / SalesN/A4,033.42398.50109.13Price / CashN/A13.1936.1356.90Price / Book0.1541.938.015.70Net Income-$110.29M-$92.79M$3.16B$248.47M7 Day PerformanceN/A1.41%2.08%2.92%1 Month Performance13.51%2.73%4.38%5.77%1 Year Performance39.49%182.00%35.81%21.39% LianBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIANLianBioN/A$0.42+1.9%N/A+32.9%$45.39MN/A-0.52110Gap UpEDITEditas Medicine4.2062 of 5 stars$2.25+7.1%$4.70+108.9%-43.6%$175.80M$32.31M0.00230Gap UpFDMT4D Molecular Therapeutics2.3394 of 5 stars$4.00+6.1%$29.56+638.9%-79.1%$174.64M$40K0.00120News CoverageAnalyst ForecastCTMXCytomX Therapeutics4.3942 of 5 stars$2.14-0.9%$5.33+149.2%+87.9%$174.14M$138.10M4.50170News CoveragePositive NewsOGIOrganigram Global1.177 of 5 stars$1.36+6.3%N/A-7.4%$171.44M$117.47M0.00860VTYXVentyx Biosciences3.1782 of 5 stars$2.41+0.4%$10.00+314.9%-5.6%$170.79MN/A0.0030Positive NewsSLSSELLAS Life Sciences Group0.7608 of 5 stars$1.77+3.5%N/A+89.3%$170.62M$1M0.0010NVCTNuvectis Pharma2.9703 of 5 stars$7.98+0.3%$17.00+113.0%+15.5%$166.31MN/A-7.068PBYIPuma Biotechnology4.2134 of 5 stars$3.36+0.3%$7.00+108.3%+14.8%$166.26M$230.50M4.36200IPHAInnate Pharma3.0054 of 5 stars$1.78-1.2%$11.00+518.3%-11.7%$165.92M$21.77M0.00220News CoverageGap DownSPROSpero Therapeutics4.223 of 5 stars$2.88-1.7%$5.00+73.6%+122.2%$163.82M$47.98M-2.25150 Related Companies and Tools Related Companies EDIT Alternatives FDMT Alternatives CTMX Alternatives OGI Alternatives VTYX Alternatives SLS Alternatives NVCT Alternatives PBYI Alternatives IPHA Alternatives SPRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIAN) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIAN Stock Alerts